PRONOUNCE compared the efficacy and safety of pemetrexed + carboplatin followed by pemetrexed ( Pem + Cb ) with paclitaxel + carboplatin + bevacizumab followed by bevacizumab ( Pac + Cb + Bev ) in patients with advanced nonsquamous non-small-cell lung cancer ( NSCLC ) .